摘要
目的通过检测进展期胃癌患者应用铂类药物新辅助化疗后标本组织中ERCCl表达水平变化，结合临床疗效进行相关性分析，探讨其作为新辅助化疗疗效生物学标志物可能性。方法通过对治疗前分期评估为第7版AJCCⅡ-Ⅲ期胃癌患者行口服氟尿嘧啶[替吉奥胶囊80mg／（m2·d），第1～14天]联合奥沙利铂（130mg／m2第l天）新辅助化疗结合外科手术，术中取得新鲜肿瘤、正常组织标本，通过RT-PCR方法从基因水平对ERCC1进行检测，分析其与新辅助化疗疗效之间的关系。结果从2012年6月-2013年3月共入组32例AJCCⅡ-III期胃癌患者，所有入组患者均完成了至少2个周期新辅助化疗，21例患者出现临床缓解（65．6％），10例患者肿瘤为组织学缓解（31．3％）。胃癌新辅助化疗有效率为65．6％。RT-PCR检测结果显示，胃癌新辅助化疗患者ERCC1表达水平病理学缓解者明显低于非敏感者（P〈0．01）。结论ERCC1表达水平变化可能成为反映以铂类药物为基础胃癌新辅助化疗疗效的重要分子生物学指标。
Objective To onalyze the impact of microRNA expression of key DNA repair signaling factor involved in processing plat- inum - induced DNA lesions（ ERCC1, excision repair cross complementation 1 ） , on treatment outcomes in locally advanced gastric cancer patients receiving preoperative oxaliplatin combined with S -1 chemotherapy. Methods We preoperativly study AJCC stage l]/lll gas- tric cancer patients received oxaliplatin （130mg/m2 ; day 1 ）and S- 1 [ 80mg/（m2 · d）; days 1 -14] every 3 weeks and subsequently performed gastrectomy with DI/D2 lymphadenectomy. Paired tumor and noimal fresh frozen tissues were collected to evaluate mRNA level of ERCCI using quantitative reverse - transcriptase polymerase chain reaction （ RT - PCR） to analyze correlation of ERCC1 with tumor response. Results Between June 2012 and March 2013, thirty - two patients were enrolled in this study. 21 （65.6%） patients had clin-ical tumor response and 10 （31.3%） patients achieved histological response. Quantitative reverse -transcriptase polymerase chain reac- tion results showed that excision repair cross complementation 1 （ ERCC1 ） mRNA expression was significantly higher in histological non - responders than responders （P 〈 0.01 ）. Conclusion ERCC1 expression may be a potential predictive biomarker in advanced gastric cancer patients treated with platinum -based chemotherapy.
出处
《医学研究杂志》
2014年第3期39-42,共4页
Journal of Medical Research
基金
全军医学科技青年培育项目计划(13QNP185)
解放军总医院临床科研扶持基金资助项目(2012FC-TSYS-2028)
